If patients aren ’t benefiting from the 340B program, who is?

The 340B Drug Pricing Program was designed to help vulnerable patients improve access to their medicines through manufacturer discounts to specific safety-net, non-profit hospitals and federally funded clinics. The biopharmaceutical industry has long supported this program, but unfortunately, 340B has strayed far from its purpose, with more and more for-profit health care entities using these discounts for themselves. Do you know just how many entities financially benefit from this supposed patient safety-net?
Source: The Catalyst - Category: Pharmaceuticals Tags: 340B Source Type: news